Biochemical pharmacology
Cajanolactone A alleviates high-fat diet-induced MAFLD by modulating liver de novo lipogenesis, inflammatory signaling, and bile acid composition in the gut-liver axis.
Zaibin Xu, Kongyan Wang, Xiaoqin Wu, Tingting Chen, Like Xu, Yi Qiu, Huiyu Hu, Yan Chen, Jiazhong Cai, Yingjie Hu, Jiawen Huang, Zhuohui Luo
Published: 202610.1016/j.bcp.2026.117717
Abstract
Metabolic dysfunction-associated fatty liver disease (MAFLD) is a common chronic liver disease worldwide, affecting more than a quarter of the adult population. Cajanolactone A (CLA), a stilbenoid derived from Cajanus cajan, has been shown to signifi…
Preview only. Read the full abstract at the source